At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 167 enrolled
Drug / intervention
NucleomaxX +1 moredrug
Likely dose
NucleomaxX 36 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Trial of Uridine Supplementation in HIV Lipoatrophy
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Mar 27, 2006·Updated Nov 4, 2021
In Brief
A Phase 3 clinical trial evaluating NucleomaxX and NucleomaxX placebo for HIV Infections and Lipoatrophy. Completed, enrolled 167 participants across 30 sites in 2 countries.
Detailed Summary
Lipoatrophy, the loss of body fat from particular areas of the body, is a common side effect of antiretroviral therapy (ART). The purpose of this study was to determine the effectiveness of uridine supplementation in treating HIV infected individuals on stable ART with lipoatrophy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections, Lipoatrophy
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2006
Enrollment StartSep 2006
Primary CompletionDec 2008
TodayJul 2026
First PostedMar 27, 2006
Enrollment StartSep 1, 2006
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 20.3 years ago
Interventions
NucleomaxXdrug
36 g sachet taken orally three times daily
NucleomaxX placebodrug
36 g placebo sachet taken orally three times daily